NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
Travera Inc
Translational Research in Oncology
Wake Forest University Health Sciences
National Cancer Institute (NCI)
Case Comprehensive Cancer Center